EUVIMEDEUVIMED entdecken
Crossref

Smart Oral Capsule with a Closed-Loop Sense–Decide–Act Strategy for Colitis Therapy

Wen Pan, Jie Fu, Shouzhe Deng, Lizhi Lin, Dingxi Lu, Jiawang Wang, Fanyu Mu, Uul Gegeen, Yihong Ding, Shuang Li iD, Dong Ming

ACS Sensors · 2026

DOI: 10.1021/acssensors.6c02826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Sensors, 2026. Verfasst von Wen Pan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Academy of Medical Engineering and Translational Medicine, Medical School, Tianjin University, Tianjin300072, China. Hauptthemen laut MEDLINE: Colitis, Budesonide, Anti-Inflammatory Agents. Die Arbeit nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatments for inflammatory bowel disease (IBD) lack real-time inflammatory monitoring and lesion-specific drug delivery, resulting in poor efficacy and systemic toxicity. To address this, we present a smart oral capsule that operates a closed-loop “sense–decide–act” strategy entirely autonomously—sensing and drug release are driven by changes in the digestive tract environment without any external intervention. The capsule features a dual-layer shell sequentially responsive to pH and matrix metalloproteinases (MMPs), enabling colon-targeted delivery and inflammation-specific activation. An integrated multimodal sensor wirelessly tracks colonic TNF-α (>5 ng mL–1), pH (>7.0), and Na+ (>100 mM). The encapsulated budesonide nanoparticles (Bud@PEG-SS-NPs) release the drug specifically in reactive oxygen species (ROS)-rich microenvironments and show superior anti-inflammatory efficacy in both lipopolysaccharide (LPS)-induced cellular models and dextran sulfate sodium (DSS)-induced mouse colitis. In live rats, the capsule achieved on-demand drug release in response to elevated local TNF-α levels, and a single intervention significantly alleviated inflammation. This work establishes a new paradigm for personalized, adaptive IBD therapy and provides a versatile platform for closed-loop management of other gastrointestinal diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisBudesonideAnti-Inflammatory AgentsAnimalsCapsulesAdministration, OralMiceTumor Necrosis Factor-alphaRatsDextran SulfateNanoparticlesDrug LiberationLipopolysaccharidesHumansPolyethylene GlycolsReactive Oxygen Species

Stichwörter der Autor:innen

IBDTNF-αaptamer sensingbiosensingingestible capsule

Substanzen

CapsulesBudesonideTumor Necrosis Factor-alphaAnti-Inflammatory AgentsDextran SulfateLipopolysaccharidesPolyethylene GlycolsReactive Oxygen Species

Autor:innen und Institutionen

  • Academy of Medical Engineering and Translational Medicine, Medical School, Tianjin University, Tianjin300072, China.

ORCID-Profile: Shuang Li

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Pan, W., Fu, J., Deng, S., Lin, L., Lu, D., Wang, J., Mu, F., Gegeen, U., Ding, Y., Li, S., & Ming, D. (2026). Smart Oral Capsule with a Closed-Loop Sense–Decide–Act Strategy for Colitis Therapy. ACS Sensors. https://doi.org/10.1021/acssensors.6c02826

Vancouver

Pan W, Fu J, Deng S, Lin L, Lu D, Wang J, et al. Smart Oral Capsule with a Closed-Loop Sense–Decide–Act Strategy for Colitis Therapy. ACS Sensors. 2026. doi:10.1021/acssensors.6c02826

BibTeX
@article{Pan2026,
  author = {Pan, Wen and Fu, Jie and Deng, Shouzhe and Lin, Lizhi and Lu, Dingxi and Wang, Jiawang and Mu, Fanyu and Gegeen, Uul and Ding, Yihong and Li, Shuang and Ming, Dong},
  title = {Smart Oral Capsule with a Closed-Loop Sense–Decide–Act Strategy for Colitis Therapy},
  journal = {ACS Sensors},
  year = {2026},
  doi = {10.1021/acssensors.6c02826}
}
Kostenlos starten →